Form 4: HCA Healthcare Executive Acquires Stock Appreciation Rights

HCA Healthcare's Senior Vice President and Controller, Christopher F. Wyatt, was granted 3,575 stock appreciation rights.

Summary

• Christopher F. Wyatt, Senior Vice President and Controller at HCA Healthcare, acquired 3,575 stock appreciation rights on January 28, 2025.
• These stock appreciation rights vest in four equal annual installments starting on January 28, 2026.
• The rights expire on January 28, 2035.
• The exercise price of the stock appreciation rights is $328.70.

Sentiment

Score: 7

Explanation: The document reflects a routine executive compensation event, which is generally positive for aligning management with shareholder interests. There are no negative implications.

Positives

• The grant of stock appreciation rights aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term performance and retention of the executive.

Industry Context

This is a standard practice for executive compensation in publicly traded companies, aligning management's interests with shareholder value.

Comparison to Industry Standards

• Stock appreciation rights are a common form of equity compensation for executives in the healthcare industry, similar to grants at companies like Tenet Healthcare and Universal Health Services.
• The vesting schedule of four years is also typical for such grants, aligning with industry norms for long-term incentive plans.

Stakeholder Impact

• The grant of stock appreciation rights is intended to align the executive's interests with those of the shareholders, potentially leading to increased shareholder value.

Key Dates

Keywords

stock appreciation rights, HCA Healthcare, executive compensation, insider trading, equity, Christopher F. Wyatt